Lenvatinib Mesylate and Pembrolizumab in Treating Patients With Metastatic or Recurrent Gastric or Gastroesophageal Cancer

Conditions:   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma;   Recurrent Gastric Carcinoma;   Stage IV Gastric Cancer AJCC v7
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Lenvatinib Mesylate;   Biological: Pembrolizumab
Sponsors:   New York University School of Medicine;   National Cancer Institute (NCI)
Recruiting

http://ift.tt/2DIClgm